Dialkyl Tryptamine Compositions for Bioavailability and Conversion Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for pure, well-characterized dialkytryptamines, including specific salts, solvates, and crystalline forms thereof, to address the therapeutic potential of psilocin for treating mood disorders, anxiety, addiction, PTSD, and other psychological and neurological disorders, as well as sexual and women's health disorders, due to the lack of availability of such compounds.
Innovation Solution
The development of dialkytryptamine compounds of formula (I) and (Ia), including their pharmaceutically acceptable salts, which can be administered alone or in compositions with excipients or other active components, to modulate neurotransmitter activity and treat various disorders through specific receptor regulation and neurogenesis modulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psilocybin is used as a prodrug of psilocin, then therapeutic potential for mood disorders is improved, but availability of pure dialkytryptamines remains insufficient
Solution Approach 1:
The patent segments the broad class of dialkytryptamines into specific enumerated compounds (compounds 1-50) with defined structural characteristics, providing pure, well-characterized substances for therapeutic use. This segmentation transforms the vague category into actionable, identifiable compounds.
Solution Approach 2:
The patent systematically varies structural parameters (R1-R8 groups) to generate a series of dialkytryptamine compounds with different properties. By changing these parameters, the patent creates a library of pure compounds with optimized characteristics for therapeutic applications.
2Manufacturing precision
If dialkytryptamine compounds are synthesized with specific structures, then purity and characterisation are improved, but complexity of compound series increases
Solution Approach 1:
The patent establishes a universal structural framework (formula I) that generates multiple compounds through systematic substitution of R1-R8 groups. This single framework serves multiple functions: defining purity standards, enabling characterisation, and providing a scalable synthesis approach for numerous compounds.
Solution Approach 2:
By changing discrete structural parameters (alkyl group types at positions R1-R8) within the unified formula I framework, the patent achieves high purity and characterisation for each compound while maintaining a manageable organizational structure that reduces overall complexity.
3Adaptability or versatility
If dialkytryptamines are developed as therapeutic agents, then treatment options for psychological disorders are improved, but bioavailability and conversion rates need optimization
Solution Approach 1:
The patent optimizes bioavailability and conversion rates by systematically varying structural parameters (R1-R8 groups) to create dialkytryptamines with different metabolic properties. This allows tuning of conversion rates to active forms and optimization of bioavailability for therapeutic use.
Solution Approach 2:
The patent identifies and utilizes prodrug compounds that serve as intermediaries, converting to active dialkytryptamine forms in the body. These prodrugs improve bioavailability and control the rate of conversion to active therapeutic forms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dialkytryptamine compounds provide effective treatment options for a range of disorders by enhancing bioavailability and adjusting the rate of conversion to active forms, offering therapeutic benefits for mood disorders, anxiety, addiction, PTSD, sexual health issues, and women's health conditions.
Implementation Method 1
to modulate neurotransmitter activity and treat various disorders through specific receptor regulation
Implementation Method 2
adjusting the rate of conversion to active forms
Data Source
AI summary
The disclosure relates to a compound of formula (1):The disclosure also relates to a compound of formula (Ia):The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).